From: Potency preservation following stereotactic body radiation therapy for prostate cancer
Characteristics | % Potent 2 years after SBRT | p value | |
---|---|---|---|
Age | |||
≤ 65 y/o pre-RT | 66.7% | 0.580 | |
>65 y/o pre-RT | 47.4% | ||
Race | |||
White | 51.2% | 0.574 | |
Non-white | 57.4% | ||
Partner status | |||
Partnered | 54.3% | 0.297 | |
Non-partnered | 55.0% | ||
Charlson comorbidity index (CCI) | |||
0 | 58.9% | 0.007* | |
≥1 | 35.3% | ||
Body mass index (BMI) | |||
< 30 | 60.9% | 0.943 | |
≥ 30 | 38.5% | ||
Risk group (D’ Amico’ s) | |||
Low risk | 54.8% | 0.420 | |
Intermediate-High Risk | 54.2% | ||
Work status | |||
Working | 54.7% | 0.173 | |
Non-working | 54.1% | ||
Pre- treatment SHIM | |||
≥ 22 | 40.91% | 0.127 | |
< 22 | 67.39% | ||
Sexual aid | |||
None | 43.8% | 0.010*# | |
Yes | 60.3% | ||
SBRT Dose | |||
36.25 Gy | 50.0% | 0.933 | |
< 36.25 Gy | 55.0% |